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A B S T R A C T   
Fibroblast growth factor (FGF) 23 produced by the bone is the principal hormone to regulate serum phosphate 
level. Serum FGF23 needs to be tightly regulated to maintain serum phosphate in a narrow range. Thus, we 
hypothesized that the bone has some phosphate-sensing mechanism to regulate the production of FGF23. Pre-
viously we showed that extracellular phosphate induces the phosphorylation of FGF receptor 1 (FGFR1) and 
FGFR1 signaling regulates the expression of Galnt3, whose product works to increase FGF23 production in vitro. 
In this study, we show the significance of FGFR1 in the regulated FGF23 production and serum phosphate level in 
vivo. We generated late-osteoblast/osteocyte-specific Fgfr1-knockout mice (Fgfr1fl/fl; OcnCre/+) by crossing the 
Ocn-Cre and the floxed Fgfr1 mouse lines. We evaluated serum phosphate and FGF23 levels, the expression of 
Galnt3 in the bone, the body weight and life span. A selective ablation of Fgfr1 aborted the increase of serum 
active full-length FGF23 and the enhanced expression of Galnt3 in the bone by a high phosphate diet. These mice 
showed more pronounced hyperphosphatemia compared with control mice. In addition, these mice fed with a 
control diet showed body weight loss after 23 weeks of age and shorter life span. These results reveal a novel 
significance of FGFR1 signaling in the phosphate metabolism and normal life span.   
1. Introduction 
Circulating level of phosphate needs to be maintained in a narrow 
range. Hypophosphatemia and hyperphosphatemia cause rickets/oste-
omalacia and ectopic calcification, respectively [1]. While several hor-
mones such as fibroblast growth factor (FGF) 23, parathyroid hormone 
(PTH), and 1,25-dihydroxyvitamin D [1,25(OH)2D] are involved in 
phosphate metabolism, FGF23 is the principal hormone to regulate 
serum phosphate level [2,3]. FGF23 is produced by the bone, especially 
by the osteoblasts and osteocytes [4], and works to reduce serum 
phosphate level by acting mainly in the kidney [3]. Namely, FGF23 
inhibits renal phosphate reabsorption in the renal proximal tubules and 
decreases 1,25(OH)2D level, which enhances intestinal phosphate ab-
sorption [3]. These facts suggest that the bone has some 
phosphate-sensing mechanism to regulate the production of FGF23 and 
serum phosphate level by FGF23. However, the precise mechanism of 
phosphate-sensing has remained to be clarified. 
We recently reported that the activation of unliganded FGF receptor 
1 (FGFR1) by extracellular phosphate regulates the production of FGF23 
[5]. We found that high extracellular phosphate induces the phosphor-
ylation of FGFR1 examined by phospho-proteomic method using oste-
oblastic UMR106 cells [5]. In addition, we demonstrated that the 
posttranslational O-glycosylation of FGF23 protein by a gene product of 
Galnt3 inhibits the proteolytic cleavage of FGF23 protein [6]. This 
posttranslational modification seemed to be the main regulatory 
mechanism of increased active full-length FGF23 level by a high phos-
phate diet in wild-type mice. FGFR1 signaling, including the phos-
phorylation of FGFR substrate (FRS) 2α and extracellular 
signal-regulated kinase (ERK), regulated the expression of Galnt3 in in 
vitro experiments [5]. Therefore, FGFR1 seemed to be a 
phosphate-sensing molecule in the regulation of FGF23 production and 
serum phosphate level. 
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Here we show the significance of FGFR1 in the regulated FGF23 
production and serum phosphate level in vivo. This study was initiated to 
generate late-osteoblast/osteocyte-specific Fgfr1-deficient mice. As a 
result, a selective ablation of Fgfr1 in bone aborted the increase of serum 
FGF23 level by a high phosphate diet. In addition, these mice showed 
more pronounced hyperphosphatemia compared with control mice by a 
high phosphate diet. Furthermore, these knockout mice fed with a 
control diet also showed shorter life span. Together with our previous 
report, these results reveal a novel unrecognized significance of FGFR1 
signaling in the phosphate metabolism and normal life span. 
2. Materials and methods 
2.1. Animals 
All animal experiments were approved by the Animal Research 
Committee at Tokushima University (T27-89). The Ocn-Cre mouse line 
was from the Jackson Laboratory (Bar Harbor, ME, USA) [7]. The floxed 
Fgfr1 mouse line was kindly provided form Dr. Juha Partanen (Univer-
sity of Helsinki, Helsinki, Finland) [8]. The mouse lines were maintained 
in C57BL/6 N background. All mice were housed in a 
specific-pathogen-free facility under climate-controlled conditions with 
a 12 h light/dark cycle. Late-osteoblast/osteocyte-specific Fgfr1-defi-
cient mice (Fgfr1fl/fl; OcnCre/+) were obtained by crossing these mice. 
Offspring was genotyped by PCR using a specific pair of primers. The 
floxed Fgfr1 allele was detected by PCR with specific primers 
5′-AATAGGTCCCTCGACGGTATC-3′ and 5′-CTGGGTCAGTGTGGA-
CAGTGT-3’. The wild-type Fgfr1 allele was detected with primers 
5′-CCCCATCCCATTTCCTTACCT-3′ and 5′-TTCTGGTGTGTCTGAAAA-
CAGCT-3’. The Ocn-Cre transgenes were detected with specific primers 
5′-CAAATAGCCCTGGCAGATTC-3′ and 5′-TGATACAAGGGA-
CATCTTCC-3’. Eight-week-old male Fgfr1-cKO mice were fed with a 
control phosphate diet containing 0.6 % phosphate (16012703, 
Research Diets, New Brunswick, NJ, USA) or a high phosphate diet 
containing 1.2 % phosphate (11101203, Research diets, New Brunswick, 
NJ, USA) for 10 days. Each diet included 0.5 % calcium and there were 
no differences in any other component. Animals were sacrificed and 
blood was collected. Before sacrifice, 24-h urine samples were collected 
using metabolic cages. The femur was removed, the epiphysis and 
adherent soft tissues were cut away, and bone marrow was flushed with 
saline. The cleaned femur was rapidly frozen in liquid nitrogen. 
2.2. Real-time RT-PCR 
Tissue samples were soaked in RNAiso Plus (Takara, Otsu, Japan) 
and homogenized with TissueLyser II (Qiagen, Venlo, Netherlands). 
Total RNA was extracted with a NucleoSpin RNA system (Machrey- 
Nagel, Duren, Germany). First-strand cDNA was synthesized from total 
RNA with PrimeScript RT Master Mix (Takara, Otsu, Japan). Real-time 
RT-PCR was performed using FastStart Essential DNA Green Master 
(Roche, Basel, Switzerland) and LightCycler 96 System (Roche, Basel, 
Switzerland). The gene expression level was normalized to that of 
β-actin (Actb). The specific primers were designed as shown in Sup-
plemental Material. 
2.3. Analysis of skeletal morphology 
Bone radiographs of the femur were taken with a soft X-ray appa-
ratus. BMD was measured by DXA using a bone mineral analyzer. These 
analyses were performed in a commercial laboratory (Kureha, Fukush-
ima, Japan). 
2.4. Serum biochemistry 
Serum levels of phosphate, calcium, urea nitrogen, and creatinine 
were measured in a commercial laboratory (SRL, Tokyo, Japan). Serum 
full-length FGF23 concentrations were measured by the FGF23 ELISA kit 
(Kainos, Tokyo, Japan) [9]. 
2.5. Statistical analysis 
Data were analyzed by two-tailed Student’s t-test or ANOVA with a 
post hoc Tukey’s test. Survival rates were evaluated by log rank test. For 
all graphs, data are represented as means ± SEMs. Statistical signifi-
cance was accepted at P < 0.05. 
3. Results 
To address the significance of FGFR1 in in vivo experiments, we first 
generated late-osteoblast/osteocyte-specific Fgfr1-deficient mice (Fgfr1- 
cKO, Fgfr1fl/fl; OcnCre/+) by crossing Osteocalcin (Ocn)-Cre transgenic 
mice [7] with mice harboring a floxed allele of Fgfr1 [8] (Fig. 1A). 
Deletion of Fgfr1 allele was observed in the calvaria and femur, but not 
in the brain, spleen, kidney, duodenum, and skin (Fig. 1B). The 
expression level of Fgfr1 in the cKO mice was almost 80 % lower than 
control in the femur, but not in the kidney (Fig. 1C). Similar expression 
level of Fgfr1 to control mice in the kidney suggested the similar FGFR1 
and α-Klotho signaling as kidney function was the same between 
Fgfr1-cKO mice and control mice (Fig. 2D and E). Fgfr1-cKO mice were 
born according to the expected Mendelian ratio and showed no change 
in the length of the body at 8 weeks of age (Fig. 1D). There was no 
difference in the increase of body weight, soft X-ray images, and bone 
mineral density (BMD) of the femur by dual-energy X-ray absorptiom-
etry (DXA) between Fgfr1-cKO mice and control mice, either (Fig. 1E–G). 
Together, there was no growth and skeletal phenotypes in Fgfr1-cKO 
mice at this age. 
Our in vitro study suggested that phosphate regulates FGF23 level 
through FGFR1 signaling [5]. To test this hypothesis in vivo, Fgfr1-cKO 
mice at 8 weeks of age were fed with a control phosphate diet with 0.6 % 
phosphate or a high phosphate diet with 1.2 % phosphate for 10 days 
(Fig. 2A). After 10 days, we analyzed serum and urine parameters, and 
gene expression in the femur. Serum phosphate level was higher in 
control mice fed with a high phosphate diet than that in mice fed with a 
control phosphate diet (Fig. 2B). On the other hand, serum phosphate 
level in Fgfr1-cKO mice fed with a control phosphate diet was as high as 
that in control mice fed with a high phosphate diet (Fig. 2B). When we 
evaluated fractional excretion of phosphate (FEPi) using 24-h urine 
samples, a high phosphate diet significantly increased FEPi independent 
of serum full-length FGF23 level in this model (Fig. 2B). Serum calcium 
level was slightly higher in Fgfr1-cKO mice fed with both a control and a 
high phosphate diet than that in control mice fed with a high phosphate 
diet (Fig. 2C). Serum urea nitrogen and creatinine levels were not 
different among these groups (Fig. 2D and E). While a high phosphate 
diet increased serum active full-length FGF23 level in control mice, a 
selective ablation of Fgfr1 in bone aborted this increase by a high 
phosphate diet (Fig. 2F). In addition, the baseline level of serum FGF23 
was lower in Fgfr1-cKO mice than that in control mice with a control diet 
(Fig. 2F). We also analyzed gene expression of Fgf23 and Galnt3, whose 
product works to increase active full-length FGF23 level, in the femur. 
The expression level of Fgf23 was suppressed in Fgfr1-cKO mice fed with 
a control phosphate diet (Fig. 2G). A selective ablation of Fgfr1 aborted 
the increase of Galnt3 expression in the femur by a high phosphate diet 
(Fig. 2G). 
Although the body size and appearance of Fgfr1-cKO mice were not 
different from those of control mice until 22 weeks of age, marked body 
weight loss of Fgfr1-cKO mice fed with a control phosphate diet was 
observed after 23 weeks of age (Fig. 3A). Moreover, the life span of 
Fgfr1-cKO mice fed with a control phosphate diet was significantly 
shorter than that of control mice (Fig. 3B). 
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4. Discussion 
This study revealed that FGFR1 signaling in the bone is necessary for 
the increase of FGF23 by a high phosphate diet and thus for the regu-
lation of serum phosphate level. On the other hand, this study also 
showed that FGFR1 in the late-osteoblasts/osteocytes is not necessary 
for skeletal development and growth. However, deletion of FGFR1 
signaling in the bone induced the body weight loss and shorter life span 
of mice in long-term observations. 
According to our previous report, we hypothesized that a selective 
ablation of Fgfr1 in the bone aborts the increase of serum active full- 
length FGF23 level and enhanced Galnt3 expression in the bone by a 
high phosphate diet [5]. This study supported this hypothesis. There-
fore, we propose that extracellular phosphate activates FGFR1 and 
increases active full-length FGF23 level through proteolytic protection 
of FGF23 protein by the gene product of Galnt3 in vivo. The identification 
of FGFR1 as a component of at least one phosphate-sensing mechanism 
is supported by previous reports suggesting the involvement of FGFR in 
the production of FGF23 in the bone [10,11]. In addition, local factors 
such as phosphate-regulating endopeptidase homolog, X-linked (PHEX) 
and dentin matrix protein 1 (DMP1), which are produced by genes 
responsible for FGF23-related hypophosphatemic rickets [1], were re-
ported to alter the production of FGF23 through FGFR signaling in the 
bone [12]. Furthermore, some activating mutations in FGFR1 cause 
osteoglophonic dysplasia associated with by high FGF23 level and 
hypophosphatemia [13]. On the other hand, it was reported that a pa-
tient with Hartsfield syndrome caused by an inactivating FGFR1 muta-
tion showed hyperphosphatemia [14]. Our hypothesis is further 
Fig. 1. Late-osteoblast/osteocyte-specific ablation of Fgfr1 in mice and their phenotypes. (A) Genomic structure of the floxed and deleted Fgfr1 alleles. Primers used 
in PCR experiments are indicated by arrows (P1, 5′-AGGTTCCCTCCTCTTGGATGA-3’; P2, 5′-CTGCATGCCAGCAGTCCCGCATC-3’; P3, 5′-AATAGGTCCCTCGACGG-
TATC-3’; P4, 5′-CTGGGTCAGTGTGGACAGTGT-3′). (B) PCR analysis of genomic DNA from each tissue in Fgfr1-cKO mice. (C) Real-time RT-PCR analysis of Fgfr1 
mRNA expression in the femur and kidney of 8-week-old control and Fgfr1-cKO mice. n = 4 mice per group. (D) Body length of 8-week-old control and Fgfr1-cKO 
mice. (E) Growth curves of control and Fgfr1-cKO mice. n = 4 mice per group. (F) Soft X-ray images of the femur of 8-week-old control and Fgfr1-cKO mice. (G) Bone 
mineral density (BMD) of the femur of 8-week-old control and Fgfr1-cKO mice. n = 4 mice per group. (B, D, and F) Data are presented as representative images. (C, E, 
and G) Data represent the mean ± SEM. *P < 0.05 by Student’s t-test; NS, not significant. 
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Fig. 2. Responses to a high phosphate diet in control and Fgfr1-cKO mice. (A) Schema of the experimental procedure. (B) Serum phosphate (Pi) and fractional 
excretion of phosphate (FEPi). (C) Serum calcium (Ca). (D) Serum urea nitrogen. (E) Serum creatinine. (F) Serum full-length FGF23. (G) Fgf23 and Galnt3 mRNA 
expression in the femurs were evaluated by real-time RT-PCR. (B–G) Data represent the mean ± SEM in control and Fgfr1-cKO mice fed a control phosphate diet (CP) 
or a high phosphate diet (HP) for 10 days. n = 8–11 mice per group. *P < 0.05 compared with control mice fed a CP diet, #P < 0.05 compared with Fgfr1-cKO mice 
fed a CP diet, †P < 0.05 compared with Fgfr1-cKO mice fed a HP diet by ANOVA with a post hoc Tukey’s test. 
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supported by the biochemical characteristics of patients with these 
human diseases. While there are some other diseases caused by FGFR1 
mutations, such as Kallmann syndrome [15] and Pfeiffer syndrome [16], 
it is unknown whether these patients show the disturbance of serum 
phosphate and FGF23 levels. We have previously shown that extracel-
lular phosphate and a canonical FGFR1 ligand, FGF2, induce different 
signals from FGFR1 [5]. It is possible that some specific signal from 
FGFR1 is essential for regulating the production of FGF23. 
Serum phosphate level was significantly increased by a high phos-
phate diet in control mice. While it is unlikely that a high phosphate diet 
causes clear increase in serum phosphate in human, oral loading of high 
phosphate seemed to exceed the excretion capacity of phosphate in the 
kidney at least in this mouse model. It was also indicated in a previous 
report that mice fed with a high phosphate diet show significant increase 
in serum phosphate level [17]. Serum phosphate level in Fgfr1-cKO mice 
fed with a high phosphate diet was not significantly different from that 
in Fgfr1-cKO mice fed with a control phosphate diet. One may expect 
much higher serum phosphate in Fgfr1-cKO mice fed with a high phos-
phate diet because FGF23 did not increase by this diet. However, FGF23 
is not the only determinant of serum phosphate level as shown by the 
similar phosphate level with quite different FGF23 in control mice with a 
high phosphate diet and Fgfr1-cKO mice with a control diet. In addition, 
Fgfr1-cKO mice fed with a high phosphate diet still showed enhanced 
renal excretion of phosphate. Because we used 24-h urine samples to 
analyze FEPi in this study, FEPi reflects daily oral intake of phosphate. 
Severe hyperphosphatemia is harmful, and it is likely that there is some 
FGF23-independent mechanism to enhance renal excretion of phosphate 
in order to prevent severe hyperphosphatemia. However, the detailed 
mechanism has not been uncovered yet. 
The increase of serum phosphate level does not seem to have an 
acute effect on the production of FGF23. In our previous study, intra-
venous administration of phosphate into healthy volunteers for 4 h 
clearly increased serum phosphate level, while no increase was observed 
in serum full-length FGF23 level [18]. In addition, in the reports by the 
other groups, the increase in serum FGF23 level by a high phosphate diet 
was seen only after a few days in human [19,20]. Furthermore, Galnt3 
induction by high phosphate peaked at 48 h in our previous in vitro 
experiments using osteoblastic UMR106 cells [5]. Thus, we presume 
that the change of serum FGF23 in response to phosphate is a rather slow 
one in contrast to rapid fluctuation of serum PTH in response to alter-
ations of serum calcium level. 
Serum calcium level in control mice fed with a high phosphate diet 
was slightly lower than that in Fgfr1-cKO mice fed with both a control 
and high phosphate diet. This may be explained by the increase of serum 
FGF23 level, which works to decrease serum 1,25(OH)2D [3], while we 
could not measure 1,25(OH)2D level because of the limited amount of 
sera. Fgfr1-cKO mice fed with a control phosphate diet showed higher 
serum phosphate level and lower FGF23 level due to suppressed Fgf23 
expression level without changing Galnt3 expression compared with 
control mice fed with a control phosphate diet. In addition, a high 
phosphate diet showed a trend to increase Fgf23 expression in Fgfr1-cKO 
mice. A high phosphate diet did not increase the expression level of 
Fgf23 in control mice as we previously showed using ICR mice [5]. While 
the enhanced expression of Galnt3 is the main reason for the increase of 
FGF23 in response to a high phosphate diet, it is suggested that FGFR1 
signaling in the bone is involved in the basal Fgf23 expression. A pre-
vious report indicated that FGF23 promoter activity was stimulated by 
FGFR1 activation in in vitro study [21]. Therefore, one explanation is 
that the reduction of FGF23 promoter activity due to the ablation of 
FGFR1 in the bone induces this phenotype. There is also a possibility 
that some other molecules than the gene product of Galnt3 are also 
involved in the regulation of Fgf23. There was non-significant trend of 
increase of Fgf23 by a high phosphate diet in Fgfr1-cKO mice. It is 
possible that a high phosphate diet affects Fgf23 expression in the 
absence of FGFR1. 
In addition, it is considered that persistently higher serum phosphate 
level in Fgfr1-cKO mice throughout the life is the reason for the body 
weight loss and shorter life span of Fgfr1-cKO mice like Fgf23-KO mice 
[2]. As there is a term “phosphate toxicity”, hyperphosphatemia is also 
well known to be associated with increased cardiovascular disease risk 
and higher mortality in both general population and patients with 
chronic kidney disease [22]. A high phosphate diet in Fgfr1-cKO mice is 
expected to increase the mortality earlier. This indicate that the main-
tenance of serum phosphate level by skeletal FGFR1 is critical for normal 
life. However, we could observe only the mortality in Fgfr1-cKO mice fed 
with a control phosphate diet and we do not have any data including 
serum level of phosphate and FGF23 in aging Fgfr1-cKO mice and the 
cause of death at this moment. 
A recent report demonstrated that extracellular phosphate induces 
type III sodium-phosphate cotransporters heterodimerization, PiT1 and 
PiT2, and mediates the activation of ERK independent of phosphate 
uptake in in vitro experiments [23]. Another recent report indicated that 
extracellular phosphate stimulates the secretion of PTH through 
calcium-sensing receptor (CaSR) on the parathyroid cells [24]. CaSR is 
also expressed in the bone [25]. Phosphate has been reported to be 
involved in several other biological responses including chondrocyte 
apoptosis [26] and development of vascular diseases [27] other than 
regulating FGF23 level. Therefore, it is possible that several molecules 
other than FGFR1 can work as phosphate-sensing mechanisms regu-
lating cell-specific functions. 
This study identified that FGFR1 is at least one of the phosphate- 
sensing molecules to regulate serum phosphate and FGF23 level in the 
bone. Our findings uncover an unrecognized function of FGFR1 and 
provide a new molecular basis of phosphate-sensing in the regulated 
FGF23 production in the bone. As the identification of CaSR has come to 
fruition of new drug discoveries for patients with primary and secondary 
hyperparathyroidism, the elucidation of the phosphate-sensing mecha-
nism may lead to the identification of novel druggable molecules for 
Fig. 3. Long-term observations in control and Fgfr1-cKO mice. (A) Changes of body weights in control and Fgfr1-cKO mice fed with a control phosphate diet. n = 10 
mice per group at the start. Data represent the mean ± SEM. *P < 0.05 by Student’s t-test. (B) Survival rates for control and Fgfr1-cKO mice fed with a control 
phosphate diet. n = 10 mice per group at the start. P value was evaluated by log rank test. 
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patients with abnormal phosphate metabolism. 
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